New antibody shot shows promise against malaria in early trial
NCT ID NCT05891236
First seen Jun 14, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-stage trial tested a lab-made antibody called MAM01 in 63 healthy adults who had never had malaria. The goal was to see if it is safe and can prevent malaria infection when people are deliberately exposed to the parasite. The study is complete, but results are not yet public.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MALARIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Center for Vaccine Development and Global Health, 685 W. Baltimore Street
Baltimore, Maryland, 21201, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MAM01 (a lab-made antibody that targets the malaria parasite)
What this could lead to
If successful, this antibody could provide temporary protection against malaria, especially for travelers or in outbreaks.
What could go wrong
This is a very early, small trial (63 people) in healthy adults who have never had malaria. It may not work in real-world settings or provide long-term protection.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.